Background: Type 2 diabetes mellitus (T2DM) presents an escalating global metabolic challenge. Contemporary biomedical strategies heavily emphasize peripheral glycaemic containment rather than addressing foundational insulin resistance. Conversely, Ayurveda approaches this pathology as Prameha (Madhumeha), deploying a multi-pronged therapeutic matrix of Ahara (dietary optimization), Vihara (circadian lifestyle modification), Shodhan (Biological Purification), and targeted herbo-mineral pharmacology. Objective: This review evaluates recent clinical evidence (2017–2026) regarding the therapeutic efficacy, safety profiles, and systemic synergy of integrative Ayurvedic protocols co-managed with conventional biomedicine for T2DM. Materials and Methods: Peer-reviewed clinical trials, systematic reviews, meta-analyses, and national public health co-management initiatives published between 2017 and 2026 were aggregated via advanced academic indexing databases. The primary outcome metrics evaluated were Glycated Haemoglobin (HbA1c), Fasting Blood Glucose (FBG), Post-Prandial Blood Glucose (PPBG), and patient-reported Quality of Life (QoL). Results: A high-fidelity systematic review encompassing 199 randomized controlled trials (RCTs) and 21,191 participants demonstrated that Ayurvedic formulations achieve statistically significant independent HbA1c reductions (0.3%–1.6%). Integrative co-management configurations (Ayurveda combined with Metformin) consistently yielded an additional ~1% absolute reduction in HbA1c compared to conventional monotherapy, alongside optimized lipid clearance and enhanced insulin sensitivity indices. Monitored case series revealed substantial metabolic correction, facilitating safe pharmaceutical de-escalation or complete biomarker normalization (e.g., baseline HbA1c reducing from 11.2% to 5.7%). Adverse events were rare and limited to mild, transient gastrointestinal adjustments. Conclusion: Integrative Ayurvedic protocols offer an effective, safe, and systemically synergistic methodology for the clinical management of T2DM. To facilitate global public health policy translation, future research must enforce rigorous reporting standards and evaluate long-term microvascular and macrovascular outcomes via large-scale multi-centric RCTs.